According to The Insight Partners research, the Asia Pacific pediatric cardiology market was valued at US$ 1,422.05 million in 2024 and is expected to reach US$ 2,295.52 million by 2031, registering a CAGR of 7.1% from 2024 to 2031. Strategic initiatives by market players and growing shift toward minimally invasive procedures are among the critical factors attributed to the Asia Pacific pediatric cardiology market expansion.
Companies operating in the global pediatric cardiology market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them boost their sales, geographic reach, and capacities to cater to a wide customer base. A few strategic initiatives taken by key players operating in the global pediatric cardiology market are mentioned below:
- In August 2024, the Alliance for Pediatric Device Innovation (APDI) partnered with Additional Ventures to solicit proposals and offer grant funding for the development of pediatric devices specifically evaluated and labeled for children with heart conditions. Additional Ventures is a nonprofit foundation focused on accelerating research progress and improving clinical care for individuals born with single-ventricle heart defects. APDI and Additional Ventures are soliciting proposals for pediatric heart devices with a US$ 300,000 grant fund.
- In May 2024, Stanford Medicine researchers developed an implantable ventricular assist device that allows children suffering from heart failure to live relatively normal lives while they get s transplant. The pump, a new type of ventricular assist device, or VAD, is surgically attached to the heart to enhance its blood-pumping action in such children, which helps delay heart failure and provide time to locate a donor's heart.
- In February 2023, Medtronic relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open- heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). The system was designed for patients suffering from RVOT anomalies who also develop severe pulmonary valve regurgitation, a condition where blood leaks into the right lower chamber of the heart after being pumped into the lungs.
Therefore, strategic initiatives by various companies focusing on the development of pediatric cardiology devices are likely to offer growth opportunities to the global pediatric cardiology market in the coming years.
On the contrary, limited number of skilled pediatric cardiologists hampers the growth of Asia Pacific pediatric cardiology market.
Based on product type, the Asia Pacific pediatric cardiology market is segmented into transcatheter heart valves, occlusion devices, catheters, stents, introducer sheaths, and others. The transcatheter heart valves segment held 48.5% share of the Asia Pacific pediatric cardiology market in 2024, amassing US$ 690.22 million. It is projected to garner US$ 1,124.77 million by 2031 to expand at 7.2% CAGR during 2024-2031.
By disease indication, the Asia Pacific pediatric cardiology market is segmented into congenital heart disease, acquired heart disease, arrhythmias, cardiomyopathies, and others. The congenital heart disease segment held 59.9% share of the Asia Pacific pediatric cardiology market in 2024, amassing US$ 851.83 million. It is projected to garner US$ 1,407.64 million by 2031 to expand at 7.4% CAGR during 2024-2031.
By surgical procedure, the Asia Pacific pediatric cardiology market is segmented into interventional procedures, heart rhythm management procedures, and others. The interventional procedures segment held 53.0% share of the Asia Pacific pediatric cardiology market in 2024, amassing US$ 753.49 million. It is projected to garner US$ 1,253.82 million by 2031 to expand at 7.5% CAGR during 2024-2031.
Based on end user, the Asia Pacific pediatric cardiology market is segmented into hospitals, specialty clinics, and others. The hospitals segment held 53.3% share of the Asia Pacific pediatric cardiology market in 2024, amassing US$ 757.81 million. It is projected to garner US$ 1,269.43 million by 2031 to expand at 7.6% CAGR during 2024-2031.
By country, the Asia Pacific pediatric cardiology market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 30.1% share of Asia Pacific pediatric cardiology market in 2024, amassing US$ 427.50 million. It is projected to garner US$ 713.39 million by 2031 to expand at 7.6% CAGR during 2024-2031.
Key players operating in the pediatric cardiology market are Abbott Laboratories, Medtronic Plc, Edwards Lifesciences Corp, Terumo Corp, W L Gore & Associates Inc, NuMED, Cordis Corp, Occlutech US LLC, Biotronik SE & Co KG, and RENATA MEDICAL, among others.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com